文章：

阿特珠单抗联合贝伐珠单抗与肝动脉灌注化疗治疗不可切除肝细胞癌的对比分析：一项多中心倾向性评分研究

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study

原文发布日期：24 August 2023

DOI: 10.3390/cancers15174233

类型: Article

开放获取: 是

英文摘要：

This study aimed to compare the prognosis and characteristics of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab (AB) combination therapy and hepatic artery infusion chemotherapy (HAIC). We retrospectively assessed 193 and 114 patients treated with HAIC and AB combination therapy, respectively, between January 2018 and May 2023. The progression-free survival (PFS) of patients treated with AB combination therapy was significantly superior to that of patients treated with HAIC (p< 0.05), but there was no significant difference in overall survival (OS). After propensity score matching, our data revealed no significant differences in OS and PFS between patients who received AB combination therapy and those who received HAIC therapy (p= 0.5617 and 0.3522, respectively). In conclusion, our propensity score study reveals no significant differences in OS and PFS between patients treated with AB combination therapy and those treated with HAIC.

摘要翻译： 

本研究旨在比较接受一线阿特珠单抗联合贝伐珠单抗（AB）联合疗法与肝动脉灌注化疗（HAIC）治疗的晚期肝细胞癌患者的预后及临床特征。我们回顾性分析了2018年1月至2023年5月期间分别接受HAIC治疗（193例）和AB联合治疗（114例）的患者。AB联合治疗组患者的无进展生存期（PFS）显著优于HAIC治疗组（p<0.05），但两组总生存期（OS）无显著差异。经倾向性评分匹配后，数据显示AB联合治疗组与HAIC治疗组在OS和PFS方面均无显著差异（p值分别为0.5617和0.3522）。综上所述，本倾向性评分研究表明，AB联合治疗与HAIC治疗在患者OS和PFS方面无显著差异。

原文链接：

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study